Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesRevive Therapeutics Ltd

Revive Therapeutics Ltd

Healthcare Drug Manufacturers - Specialty & Generic
PortfolioPortfolio WatchlistWatchlist
Company price
0.02 CAD 0.01 ( 33.33%)
Last update at 2026-11-10T17:04:00Z
VOLUME
5018
Market Cap
17.43M

Momentum Score

…

Revive Therapeutics Ltd., a life sciences company, focuses on the research and development of therapeutics and diagnostics for infectious diseases, medical countermeasures, and rare disorders. It develops Bucillamine, a disease-modifying anti-rheumatic drug, for the treatment of infectious diseases, including influenza and COVID-19, as well as to treat pandemic influenza, emerging infectious diseases, and medical countermeasure incidents and attacks. The company also develops Psilocybin, which is in Phase 1 clinical study for treating methamphetamine use disorder; and Psilocin for the treatment of depression, anxiety, bi-polar disorder, bulimia and anorexia nervosa, and other diseases. Revive Therapeutics Ltd. is based in Toronto, Canada.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.02
Low
0.02
High
52 Week Price Range
0.01
Low
0.08
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Revive Therapeutics Ltd is a Canada-listed biotechnology company developing small-molecule and psychedelic-derived treatments for infectious, inflammatory and mental health conditions. Long-term growth could be supported by clinical program progress, intellectual property development and strategic collaborations that help advance commercialization. Investors may find exposure to a diversified pipeline appealing for potential upside if programs advance.

The primary risks are early-stage clinical and regulatory uncertainty, limited revenue history and likely need for additional financing that could dilute shareholders, alongside competitive and execution challenges.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.01
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
0.01
ROE
-805.70%
Net Debt
0.05M
ROCE
49.82%
Diluted EPS TTM
-0.03

Insight News

View All

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Income before tax -11.01M -5.62M -6.32M -17.81M -20.12M
Net income -11.01M -5.62M -6.32M -17.81M -20.12M
Selling general administrative 1.40M 2.18M 1.94M 2.68M 11.87M
Reconciled depreciation 0.00M 0.00M 0.00M 0.00M 0.00M
Ebit - - - -17.78M -18.57M
Ebitda - - - -17.74M -20.04M
Operating income -1.65M -5.61M -6.39M -17.87M -20.30M
Interest expense 0.00M 0.02M 0.04M 0.06M 0.08M
Interest income 0.00M 0.00M 0.07M 0.06M 0.18M
Net interest income -0.00M 0.04M 0.06M 0.05M 0.02M
Total revenue 0.00M 0.00M 0.00M 0.00M 0.00M
Total operating expenses 1.65M 3.29M 5.52M 17.83M 18.59M
Total other income expense net -9.36M -2.37M -0.86M -0.03M -1.54M
Net income from continuing ops -11.01M -5.62M -6.32M -17.81M -20.12M
Net income applicable to common shares - -5.62M -6.32M -17.81M -20.12M
Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Total assets 0.21M 10.64M 14.25M 17.07M 29.81M
Intangible assets - 9.38M 11.72M 12.50M 12.50M
Other current assets - 0.05M 0.05M - -
Total liab 3.66M 3.40M 3.60M 4.46M 1.00M
Total stockholder equity -3.46M 7.23M 10.65M 12.60M 28.81M
Common stock - 47.50M 45.98M 43.11M 42.43M
Capital stock 47.70M 47.50M 45.98M 43.11M 42.43M
Retained earnings -77.20M -63.78M -47.98M -54.25M -36.44M
Other liab - - - 0.08M 0.07M
Other assets - - - 0.15M 0.26M
Cash 0.01M 0.77M 2.09M 3.92M 16.60M
Cash and equivalents - 0.77M 2.09M 3.92M 16.60M
Total current liabilities 3.51M 3.32M 3.44M 4.17M 0.60M
Net debt 0.05M - - - -
Short term debt - 0.00M 0.00M 0.00M 0.00M
Short long term debt total - - - - 0.33M
Other stockholder equity - - - 11.34M 11.43M
Property plant equipment - 0.00M 0.00M 0.00M 0.00M
Total current assets 0.07M 1.14M 2.35M 4.16M 16.79M
Long term investments 0.14M 0.12M 0.16M 0.25M 0.25M
Net tangible assets - - - 0.10M 16.31M
Short term investments - - - - 0.00M
Net receivables - - - 0.19M 0.13M
Long term debt 0.07M 0.00M 0.06M 0.06M 0.06M
Accounts payable 2.65M 2.58M 2.66M 3.92M 0.44M
Non current assets total 0.14M 9.50M 11.90M 12.90M 13.01M
Capital lease obligations 0.00M 0.03M 0.16M 0.27M 0.36M
Long term debt total - 0.00M 0.09M 0.22M 0.33M
Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Investments -0.03M 0.00M - 0.00M 0.28M
Change to liabilities - - - 3.58M 0.21M
Total cashflows from investing activities - - - 0.00M -2.72M
Net borrowings 0.04M -0.04M 0.00M -0.15M -0.13M
Total cash from financing activities 0.04M 1.98M 4.20M 0.38M 26.24M
Change to operating activities - - - -0.03M 0.50M
Net income -11.01M -5.62M -6.32M -17.81M -20.12M
Change in cash -0.76M -1.31M -1.83M -12.68M 15.22M
Begin period cash flow 0.77M 2.09M 3.92M 16.60M 1.38M
End period cash flow 0.01M 0.77M 2.09M 3.92M 16.60M
Total cash from operating activities -0.77M -3.29M -6.03M -13.06M -8.31M
Issuance of capital stock 0.00M 2.02M 4.20M 0.38M 28.67M
Depreciation 0.00M 0.00M 0.00M 0.00M 0.00M
Other cashflows from investing activities - - - 0.00M 0.28M
Sale purchase of stock - 2.02M 4.20M 0.38M 28.67M
Other cashflows from financing activities - - - 0.15M -2.30M
Change to netincome - - - 1.20M 11.11M
Capital expenditures 0.00M 0.00M 0.00M 0.00M 3.00M
Change in working capital 0.60M -0.19M -0.75M 3.54M 0.71M
Stock based compensation 0.12M 0.14M 0.00M 1.04M 8.57M
Other non cash items 0.20M -0.02M 0.18M 0.14M 0.98M
Free cash flow -0.77M -3.29M -6.03M -13.06M -11.31M

Peer Comparison*

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Stock Name
Change
(CAD)
Price
(CAD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
RVV
Revive Therapeutics Ltd		 0.01
33.33%		 0.02 - - - 0.73 -2.39
GTII
Green Thumb Industries Inc		 0.04
0.43%		 9.28 14.70 34.84 1.91 0.86 3.95
CL
Cresco Labs Inc		 0.02
2.67%		 0.77 - 105.26 0.70 0.99 42.44
JUSH
Jushi Holdings Inc		 -0.01
1.59%		 0.62 - 17.86 0.52 0.69 9.56
GRIN
Grown Rogue International Inc		 -0.01
2.08%		 0.47 23.50 - 3.62 4.10 11.19

Profile*

Revive Therapeutics Ltd

Revive Therapeutics Ltd., a life sciences company, focuses on the research and development of therapeutics and diagnostics for infectious diseases, medical countermeasures, and rare disorders. It develops Bucillamine, a disease-modifying anti-rheumatic drug, for the treatment of infectious diseases, including influenza and COVID-19, as well as to treat pandemic influenza, emerging infectious diseases, and medical countermeasure incidents and attacks. The company also develops Psilocybin, which is in Phase 1 clinical study for treating methamphetamine use disorder; and Psilocin for the treatment of depression, anxiety, bi-polar disorder, bulimia and anorexia nervosa, and other diseases. Revive Therapeutics Ltd. is based in Toronto, Canada.

The Canadian Venture Building, Toronto, ON, Canada, M5C 1P1

888-901-0036

https://revivethera.com

Name Title Year Born
Mr. Michael Frank Chairman & CEO 1961
Mr. Carmelo Marrelli ACIS, B.Comm., C.A., C.P.A., CGA Chief Financial Officer 1971
Dr. Kelly T. McKee Jr., M.D., M.P.H. Chief Scientific Officer Consultant 1950
Dr. Onesmo Mpanju Ph.D. Chief Regulatory Affairs Consultant NA
Dr. Kelly T. McKee Jr., M.D., M.P.H. Chief Scientific Officer Consultant 1951

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

DRUG
CAD 32.00
+23.08%
CHR
CAD 35.50
+7.80%
HG
CAD 4.77
+7.19%
QTWO
CAD 1.73
+7.14%
PET
CAD 23.03
+7.02%
MUX
CAD 18.80
-17.69%
URE
CAD 0.96
-15.04%
WELL
CAD 3.62
-14.82%
ITH
CAD 2.01
-10.67%
SGML
CAD 7.52
-9.94%

Equity Sectors*

  • Basic Materials

    -3.56%

  • Communication Services

    +0.11%

  • Consumer Cyclical

    -0.57%

  • Consumer Defensive

    -0.30%

  • Energy

    +0.19%

  • Financial Services

    -0.06%

  • Healthcare

    -0.37%

  • Industrials

    -0.81%

  • Real Estate

    -0.85%

  • Technology

    -0.12%

  • Utilities

    -0.11%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…